Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke

Prior treatment

• Participate in other drug or device clinical trials within 28 days prior to screening visit

Other illness

• Known allergies to heparin, narcotic drugs, contrast agents, and/or antiplatelet medications such as aspirin and clopidogrel
• mRS ≥ 2 before stroke
• Refractory hypertension that cannot be controlled by medication (systolic blood pressure ≥185mmHg, or diastolic blood pressure ≥110mmHg)
• Patients with any of the following exclusion criteria were not eligible to participate in this study
  • Preoperative CT or MRI showed bleeding symptoms
  • CT or MRI shows intracranial mass or intracranial tumor requiring surgical treatment
  • Angiography revealed carotid dissection or extracranial occlusion or arteritis of the carotid artery
  • Angiography revealed simultaneous acute obstruction of both carotid systems

Lab values

• Bleeding prone predisposition with severe coagulopathy, such as INR \> 3.0 or platelet count \< 40x10∧9/L
• Blood glucose at screening was \< 2.8mmol/L or \> 22 mmol/L

Other

• Pregnant Or Lactating Women
• Hemorrhagic cerebrovascular history within 3 months

• Age 18-85
• Within 8 hours of the onset of stroke symptoms
• There are clinical signs and symptoms consistent with acute ischemic stroke
• Imaging examination excluded intracranial hemorrhage, and there were no imaging changes of early large cerebral infarction (large infarction was defined as the aspect score of CT or DWI image \< 6, infarct volume ≥70ml or infarct area \> 1/3MCA)
• Patients with imaging evidence of stroke caused by occlusion of the internal carotid artery (intracranial segment) or the M1/M2 segment of the middle cerebral artery or the A1/A2 segment of the anterior cerebral artery without clear contraindications
• 6 points ≤NIHSS score \< 30 points
• Informed consent is signed by the patient or her legal guardian